Document is current
Any future updates will be listed below
-
Authors
Perlman, Susan https://orcid.org/0000-0002-7208-2418
Anheim, Mathieu https://orcid.org/0000-0001-8121-0605
Boesch, Sylvia https://orcid.org/0000-0003-1657-7368
Lewis, James H. https://orcid.org/0000-0002-6686-3744
Lynch, David R. https://orcid.org/0000-0001-7168-214X
-
Funding
Funding for this research was provided by:
Biogen
- License Information
-
More Information
Article History
Received: 4 March 2025
Accepted: 10 April 2025
First Online: 2 June 2025
Declarations
:
: Susan Perlman has received grant funding from Reata Pharmaceuticals; Reata was acquired by Biogen in 2023. Mathieu Anheim has received honoraria from Ipsen, AbbVie, Orkyn, Teva, Reata Pharmaceuticals, Biogen, Aguettant, Merz, Ever Pharma, Asdia. Sylvia Boesch has received fees for consultancy, advisory boards, and/or honoraria from AbbVie, Ipsen, Reata Pharmaceuticals, Merz Pharma, Stada Arzneimittel, and VICO Therapeutics. James H. Lewis was a consultant to Reata Pharmaceuticals. David R. Lynch has received grants through the Children’s Hospital of Philadelphia from the National Institutes of Health, US Food and Drug Administration, Friedreich’s Ataxia Research Alliance (FARA), Reata Pharmaceuticals, PTC Therapeutics, Design Therapeutics, Stealth BioTherapeutics, and Voyager Therapeutics.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
